Multifaceted modes of action of azacytidine: a riddle wrapped up in an enigma

Leuk Lymphoma. 2019 Dec;60(13):3277-3281. doi: 10.1080/10428194.2019.1627542. Epub 2019 Jun 12.

Authors

Eleftheria Lamprianidou¹, Emmanouela Zoulia¹, Elsa Bernard², Chryssoula Kordella¹, Menelaos Papoutselis¹, Zoi Bezirgiannidou¹, George Vrachiolias¹, Elli Papaemmanuil², Ioannis Kotsianidis¹

Affiliations

¹ Department of Hematology, Democritus University of Thrace Medical School, Alexandroupolis, Greece.
² Center for Molecular Oncology, Center for Heme Malignancies and Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

PMID: 31185765
DOI: 10.1080/10428194.2019.1627542

No abstract available

Publication types

Case Reports
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Antimetabolites, Antineoplastic / pharmacology*
Antimetabolites, Antineoplastic / therapeutic use
Azacitidine / pharmacology*
Azacitidine / therapeutic use
Biopsy
Bone Marrow / drug effects
Bone Marrow / pathology
DNA Methylation / drug effects*
DNA Mutational Analysis
Disease Progression
Drug Resistance, Neoplasm / genetics
Epigenesis, Genetic / drug effects
Fatal Outcome
Gene Expression Regulation, Neoplastic / drug effects*
Humans
Karyotyping
Male
Middle Aged
Mutation
Myelodysplastic Syndromes / drug therapy*
Myelodysplastic Syndromes / genetics
Myelodysplastic Syndromes / pathology
Treatment Outcome

Substances

Antimetabolites, Antineoplastic
Azacitidine